Fig. 4

miR-493-5p promotes the sensitivity of Molm13 cells to AraC by targeting METTL3. A, The expression of METTL3 in Molm13 cells treated with oe-METTL3 and in Molm13 R cells treated with sh-METTL3-1 or sh-METTL3-2 measured by RT-qPCR. Molm13 cells were treated with AraC (2 μM) + oe-METTL, and Molm13 R cells were treated with AraC (2 μM) + sh-METTL. B, The expression of METTL3 in Molm13 and Molm13 R cells measured by RT-qPCR. C, The viability of Molm13 and Molm13 R cells evaluated using CCK-8 assay. D, The apoptosis of Molm13 and Molm13 R cells assessed using flow cytometry. E, The expression of Bcl-2, Bax, and cleaved caspase-3 proteins in Molm13 and Molm13 R cells determined by Western blot analysis. Molm13 cells were treated with AraC (2 μM) + miR-493-5p inhibitor + sh-METTL3, and Molm13 R cells were treated with AraC (2 μM) + miR-493-5p mimic + oe-METTL3. F, Determination of METTL3 expression in Molm13 and Molm13 R cells by RT-qPCR. G, Viability of Molm13 and Molm13 R cells assessed by CCK-8 assay. H, Apoptosis of Molm13 and Molm13 R cells determined by flow cytometry. I, Protein expression of Bcl-2, Bax, and cleaved caspase-3 in Molm13 and Molm13 R cells determined using Western blot analysis. * p < 0.05. Cell experiments were performed three times independently